Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Helicos BioSciences's Enterprise Value is €0.00 Mil.
Helicos BioSciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2011 was €-4.60 Mil. Therefore, Helicos BioSciences's EV-to-EBIT ratio for today is 0.00.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Helicos BioSciences's Enterprise Value is €0.00 Mil.
Helicos BioSciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2011 was €-4.59 Mil. Therefore, Helicos BioSciences's EV-to-EBITDA ratio for today is 0.00.
Helicos BioSciences Enterprise Value Historical Data
The historical data trend for Helicos BioSciences's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Helicos BioSciences's Enterprise Value
For the Drug Manufacturers - Specialty & Generic subindustry, Helicos BioSciences's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Helicos BioSciences's Enterprise Value Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Helicos BioSciences's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Helicos BioSciences's Enterprise Value falls into.
Helicos BioSciences Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Helicos BioSciences's Enterprise Value for the fiscal year that ended in Dec. 2011 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helicos BioSciences (FRA:HB4) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Helicos BioSciences's current Enterprise Value is €0.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Helicos BioSciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2011 was €-4.60 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Helicos BioSciences's current Enterprise Value is €0.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Helicos BioSciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2011 was €-4.59 Mil.
Helicos BioSciences's current Enterprise Value is €0.00 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Helicos BioSciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2011 was €2.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Helicos BioSciences Enterprise Value Related Terms
Thank you for viewing the detailed overview of Helicos BioSciences's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Helicos BioSciences (FRA:HB4) Business Description
Helicos BioSciences Corp is incorporated in the state of Delaware and was incorporated on May 9, 2003. It is a life sciences company focused on genetic analysis technologies for the research, drug discovery and clinical diagnostics markets. The Company's products are based on its proprietary True Single Molecule Sequencing (tSMS) technology which enables rapid analysis of large quantities of genetic material by directly sequencing single molecules of DNA or single DNA copies of RNA. The Company's Helicos Genetic Analysis Platform is designed to obtain sequencing information by repetitively performing a cycle of biochemical reactions on individual DNA molecules and imaging the results after each cycle. The platform consists of an instrument called the HeliScope Single Molecule Sequencer, an image analysis computer tower called the HeliScope Analysis Engine, associated reagents, which are chemicals used in the sequencing process, and disposable supplies. The Company is subject, both directly and indirectly, to the adverse impact of existing and potential future government regulation of its operations and markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:HB4 has been successfully added to your